Analgesics and Anti-inflammatory Drugs Practice Questions

Q: Morphine is used in the treatment of which one of the following conditions?

Left ventricular failure. **Explanation:** Morphine is a cornerstone in the management of **Acute Left Ventricular Failure (LVF)** and acute pulmonary edema [1]. Its therapeutic benefit is derived from several key pharmacological actions: 1. **Venodilation:** Morphine increases peripheral venous capacitance (venodilator effect), which reduces **preload**. This decreases the workload on the failing heart and relieves pulmonary congestion. 2. **Arteriodilation:** It reduces systemic vascular resistance (**afterload**), further improving cardiac output. 3. **Anxiolysis:** By relieving the intense anxiety and "air hunger" associated with dyspnea, it reduces sympathetic overactivity [1]. 4. **Respiratory Depression:** It reduces the tachypnea and the work of breathing, making the patient’s respiratory effort more efficient [1]. **Why the other options are incorrect:** * **Asthma:** Morphine is strictly **contraindicated** in bronchial asthma because it triggers histamine release from mast cells, leading to bronchoconstriction. Furthermore, its respiratory depressant effect can be fatal during an acute attack. * **Kyphoscoliosis & Chronic Cor Pulmonale:** These conditions are characterized by a diminished respiratory reserve and chronic hypercapnia. Morphine suppresses the respiratory center and can precipitate acute respiratory failure in these patients [2]. **High-Yield Clinical Pearls for NEET-PG:** * **Specific Antidote:** Naloxone is the drug of choice for morphine poisoning. * **Miosis:** Morphine causes "pin-point pupils" via stimulation of the Edinger-Westphal nucleus (tolerance does not develop to this effect). * **Biliary Colic:** Morphine is generally avoided in biliary colic as it causes spasm of the **Sphincter of Oddi** (Pentazocine or Buprenorphine are preferred). * **Contraindications:** Head injury (increases ICP), Undiagnosed abdominal pain, and Hypothyroidism.

Q: Prostaglandins are used in all except?

Palliative treatment of Patent Ductus Arteriosus (PDA). The correct answer is **D. Palliative treatment of Patent Ductus Arteriosus (PDA)**. ### **Explanation of the Correct Answer** The goal in managing a **Patent Ductus Arteriosus (PDA)** is usually to **close** it, not maintain it. Prostaglandins (specifically PGE1) are used to **keep the ductus arteriosus open** in neonates with ductal-dependent congenital heart defects (e.g., Transposition of the Great Arteries) [1, 2]. To treat/close a PDA, **NSAIDs** (Prostaglandin synthesis inhibitors) like **Indomethacin** or **Ibuprofen** are used. Therefore, prostaglandins are not used for the treatment of PDA itself. ### **Analysis of Incorrect Options** * **A. Cervical Ripening:** **PGE2 (Dinoprostone)** and **PGE1 (Misoprostol)** are gold-standard agents used to soften the cervix and induce labor by increasing proteoglycan synthesis and collagenase activity [1, 2, 3, 4]. * **B. Postpartum Hemorrhage (PPH):** **PGF2α (Carboprost)** and **PGE1 (Misoprostol)** are potent uterotonics used to control bleeding by causing strong uterine contractions when oxytocin is insufficient [2, 4]. * **C. Erectile Dysfunction:** **PGE1 (Alprostadil)** can be injected intracavernosally or applied intraurethrally. It acts as a vasodilator by increasing cAMP, facilitating an erection [2]. ### **High-Yield NEET-PG Pearls** * **Alprostadil (PGE1):** Used for maintaining ductal patency (pre-surgery) and Erectile Dysfunction [1, 2]. * **Misoprostol (PGE1):** Used for NSAID-induced peptic ulcers, medical abortion (with Mifepristone), and PPH [2, 3, 4]. * **Latanoprost (PGF2α):** First-line for Open-Angle Glaucoma (increases uveoscleral outflow) [2, 3]. * **Epoprostenol (PGI2):** Used in Pulmonary Arterial Hypertension [2]. * **Closure of PDA:** Remember the mnemonic "Come In" (**C**lose with **I**ndomethacin); **Keep Open** with **PGE1** [1, 2].

Q: Abatacept is a new drug approved for which of the following conditions?

Rheumatoid Arthritis. **Explanation:** **Abatacept** is a selective T-cell costimulation modulator. Its mechanism of action involves binding to **CD80 and CD86** on antigen-presenting cells (APCs). By doing so, it blocks the interaction with **CD28** on T-cells, which is the "second signal" required for T-cell activation. Without this costimulatory signal, T-cells cannot become fully activated, thereby reducing the inflammatory cascade in the synovium. * **Why Rheumatoid Arthritis (RA) is correct:** Abatacept is FDA-approved for the treatment of moderate-to-severe RA in patients who have had an inadequate response to conventional DMARDs (like Methotrexate) or TNF-inhibitors. It is also used in Juvenile Idiopathic Arthritis (JIA) and Psoriatic Arthritis. * **Why other options are incorrect:** While SLE, Sjogren’s, and Scleroderma are autoimmune conditions, Abatacept is not a first-line or standard approved therapy for them. Clinical trials for Abatacept in SLE and Sjogren’s have largely failed to meet primary endpoints or remain experimental. **High-Yield Clinical Pearls for NEET-PG:** 1. **Mechanism:** It is a fusion protein consisting of the extracellular domain of **CTLA-4** fused to the Fc portion of human IgG1. 2. **Contraindication:** It should **not** be used concurrently with TNF-alpha inhibitors (e.g., Etanercept, Infliximab) due to an increased risk of serious infections. 3. **Screening:** Patients must be screened for **Latent Tuberculosis** and Hepatitis B before starting therapy, similar to other biological DMARDs. 4. **Mnemonic:** "Abata-**C**ept blocks **C**D80/86" (The **C**TLA-4 component).

Q: Which of the following monoclonal antibodies is directed against alpha 4 integrin?

Natalizumab. **Explanation:** **Natalizumab** is a humanized monoclonal antibody that targets the **$\alpha$4-subunit of integrins** ($\alpha$4$\beta$1 and $\alpha$4$\beta$4) [1], [2]. These integrins are expressed on the surface of all leukocytes except neutrophils [1]. By binding to $\alpha$4-integrin, Natalizumab prevents leukocytes from adhering to the Vascular Cell Adhesion Molecule-1 (VCAM-1) on the blood-brain barrier and intestinal lining [2]. This inhibits the migration of inflammatory cells into the CNS and gut, making it highly effective for **Multiple Sclerosis** and **Crohn’s disease** [1], [2]. **Analysis of Incorrect Options:** * **Efalizumab:** Targets **CD11a**, a subunit of Leukocyte Function-associated Antigen-1 (LFA-1). It was used for psoriasis but was withdrawn due to the risk of Progressive Multifocal Leukoencephalopathy (PML). * **Ibalizumab:** A "post-attachment inhibitor" that binds to the **CD4 receptor**, preventing HIV-1 from entering host cells. * **Tocilizumab:** An **Interleukin-6 (IL-6) receptor antagonist** used in Rheumatoid Arthritis, Giant Cell Arteritis, and Cytokine Release Syndrome (CRS). **High-Yield Clinical Pearls for NEET-PG:** * **PML Risk:** The most significant adverse effect of Natalizumab is **Progressive Multifocal Leukoencephalopathy (PML)**, caused by the reactivation of the **JC virus** [2]. Patients must be screened for anti-JCV antibodies before starting therapy. * **Integrin Targets:** * $\alpha$4$\beta$7 integrin (gut-specific): **Vedolizumab** (used in Ulcerative Colitis). * $\alpha$IIb$\beta$3 integrin (platelets): **Abciximab** (antiplatelet agent). * **Mnemonic:** "Nata-**4**-zumab" for **$\alpha$4**-integrin.

Q: Which of the following is NOT a rheumatoid disease modifying drug?

BAL. **Explanation:** The correct answer is **BAL (British Anti-Lewisite)**. **1. Why BAL is the correct answer:** BAL, also known as **Dimercaprol**, is a **chelating agent**, not a Disease-Modifying Anti-Rheumatic Drug (DMARD). It is used primarily in the treatment of acute poisoning by heavy metals such as arsenic, mercury, and gold. It works by forming stable, non-toxic, soluble complexes with metal ions, which are then excreted in the urine. It has no role in modifying the autoimmune pathophysiology of Rheumatoid Arthritis (RA). **2. Why the other options are incorrect:** * **Chloroquine/Hydroxychloroquine:** These are **Antimalarials** used as "Conventional Synthetic DMARDs." They are preferred for mild RA or in combination therapy (Triple Therapy) due to their relatively low toxicity. * **Gold (Chrysotherapy):** Historically, gold salts (e.g., Sodium aurothiomalate) were mainstay DMARDs. They inhibit macrophage phagocytosis and lysosomal enzyme release. Though rarely used today due to toxicity, they are classified as DMARDs. * **Penicillamine:** This is a degradation product of penicillin that acts as a DMARD by reducing the numbers of T-lymphocytes and inhibiting collagen cross-linking. Like gold, its use has declined due to the availability of safer alternatives like Methotrexate. **3. High-Yield Clinical Pearls for NEET-PG:** * **DMARD of Choice:** Methotrexate is the "Gold Standard" and first-line DMARD for Rheumatoid Arthritis. * **BAL Contraindication:** It should not be used in **Iron or Cadmium poisoning** as the resulting complex is nephrotoxic. * **Ocular Toxicity:** Patients on Hydroxychloroquine require regular ophthalmological screening for **"Bull’s eye maculopathy."** * **Triple Therapy for RA:** Includes Methotrexate + Sulfasalazine + Hydroxychloroquine.

Q: Anti-TNF alpha drugs are used for the treatment of all the following diseases EXCEPT:

Systemic lupus erythematosus. **Explanation:** Anti-TNF alpha agents (e.g., Infliximab, Adalimumab, Etanercept) are potent biological DMARDs that neutralize Tumor Necrosis Factor-alpha, a key pro-inflammatory cytokine. **Why Systemic Lupus Erythematosus (SLE) is the correct answer:** While TNF-alpha is involved in many autoimmune processes, anti-TNF drugs are generally **avoided in SLE**. In fact, these drugs are known to induce a "Lupus-like syndrome" (Drug-induced Lupus) characterized by the development of Anti-nuclear antibodies (ANA) and Anti-dsDNA antibodies. Using them in a patient with pre-existing SLE can exacerbate the disease or cause paradoxical flares. **Why the other options are incorrect:** * **Seronegative arthritis:** This group (including Ankylosing Spondylitis) is characterized by high TNF-alpha levels in the entheses and joints. Anti-TNF drugs are the gold standard for patients non-responsive to NSAIDs. * **Psoriatic arthritis:** TNF-alpha plays a central role in both skin plaque formation and joint destruction. These drugs are highly effective in treating both the cutaneous and articular manifestations. * **Crohn’s disease:** TNF-alpha is a primary driver of intestinal inflammation. Monoclonal antibodies like Infliximab are mainstay treatments for moderate-to-severe or fistulizing Crohn’s disease. **NEET-PG High-Yield Pearls:** 1. **Screening:** Always screen for **Latent Tuberculosis** (via TST or IGRA) and Hepatitis B before starting anti-TNF therapy, as these drugs can cause reactivation. 2. **Drug-Induced Lupus:** Among anti-TNF agents, **Infliximab** and **Etanercept** are most commonly associated with positive ANA titers. 3. **Contraindications:** Avoid anti-TNF drugs in patients with NYHA Class III/IV **Heart Failure** and demyelinating diseases like Multiple Sclerosis.

Q: Which of the following analgesic is used in arthritis and has a synovial fluid to plasma concentration ratio of 3:1?

Diclofenac. **Explanation:** **Diclofenac** is the correct answer due to its unique pharmacokinetic profile. While most NSAIDs have high plasma protein binding, Diclofenac exhibits a significant "preferential accumulation" in the synovial fluid. Although its plasma half-life is short (approx. 1–2 hours), it persists in the synovial fluid for much longer. The **synovial fluid to plasma concentration ratio is approximately 3:1**, making it exceptionally effective for chronic joint conditions like osteoarthritis and rheumatoid arthritis, as it provides prolonged local therapeutic effects despite low systemic levels. **Analysis of Incorrect Options:** * **Ibuprofen (A):** It has a short half-life (2 hours) and penetrates the synovial fluid, but it does not achieve the 3:1 concentration ratio seen with Diclofenac. Its concentrations in the joint are generally lower than or equal to plasma levels. * **Tenoxicam (C) & Piroxicam (D):** These are oxicam derivatives characterized by very **long plasma half-lives** (approx. 50–70 hours). While they are used in arthritis, they do not show the specific 3:1 synovial-to-plasma ratio; rather, they maintain steady-state concentrations in both compartments due to their slow elimination. **High-Yield NEET-PG Pearls:** * **Mechanism:** Diclofenac is a non-selective COX inhibitor but also slightly inhibits the lipoxygenase (LOX) pathway and reduces intracellular arachidonic acid concentrations. * **Toxicity:** Diclofenac is associated with a higher risk of **hepatotoxicity** compared to other NSAIDs. * **Formulations:** It is often combined with Misoprostol (a PGE1 analog) to prevent NSAID-induced peptic ulcers. * **Topical Advantage:** Due to its high potency and tissue penetration, it is the most commonly used topical NSAID gel.

Question 1

Morphine is used in the treatment of which one of the following conditions?

Accepted Answer

Left ventricular failure

Answer

Asthma

Answer

Kyphoscoliosis

Answer

Chronic cor pulmonale

Question 2

Prostaglandins are used in all except?

Accepted Answer

Palliative treatment of Patent Ductus Arteriosus (PDA)

Answer

Cervical ripening

Answer

Postpartum hemorrhage (PPH)

Answer

Erectile dysfunction

Question 3

Abatacept is a new drug approved for which of the following conditions?

Accepted Answer

Rheumatoid Arthritis

Answer

Systemic Lupus Erythematosus (SLE)

Answer

Sjogren Syndrome

Answer

Scleroderma

Question 4

What is the mechanism of analgesia?

Accepted Answer

Nicotinic and cholinergic receptors

Answer

Nociceptin stimulation

Answer

Nocistatin stimulation

Answer

Anandamide receptors

Question 5

What is true about febuxostat?

Accepted Answer

It is an anti-gout medication and a xanthine oxidase inhibitor.

Answer

It is a purine inhibitor.

Answer

Dose adjustment is required in renal impairment.

Answer

It has uricosuric action.

Question 6

Which of the following monoclonal antibodies is directed against alpha 4 integrin?

Accepted Answer

Natalizumab

Answer

Efalizumab

Answer

Ibalizumab

Answer

Tocilizumab

Question 7

Which of the following is NOT a rheumatoid disease modifying drug?

Accepted Answer

BAL

Answer

Chloroquine

Answer

Gold

Answer

Penicillamine

Question 8

Anti-TNF alpha drugs are used for the treatment of all the following diseases EXCEPT:

Accepted Answer

Systemic lupus erythematosus

Answer

Seronegative arthritis

Answer

Psoriatic arthritis

Answer

Crohn's disease

Question 9

Which of the following analgesic is used in arthritis and has a synovial fluid to plasma concentration ratio of 3:1?

Accepted Answer

Diclofenac

Answer

Ibuprofen

Answer

Tenoxicam

Answer

Piroxicam

Question 10

Which of the following statements about COX-2 is FALSE?

Accepted Answer

Activation of COX-2 leads to an ulceroprotective effect on the gastric mucosa.

Answer

COX-2 is constitutively expressed on some cell surfaces.

Answer

COX-2 is induced at the site of inflammation.

Answer

COX-2 is utilized in the generation of eicosanoids with a ring structure.

Analgesics and Anti-inflammatory Drugs — MCQs

Analgesics and Anti-inflammatory Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?